CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Brain Cancer Drug IND Filing Accepted for Review by FDA
CNS Pharmaceuticals featured in audio broadcast distributed to thousands of syndication points. Berubicin IND accepted for review by FDA Phase 1 trial showed 44% of patients experiencing clinical benefit of stable disease or better Adult Phase 2 trials to commence in Q1 2021 The IND filing for brain cancer drug Berubicin has been accepted for review by the U.S. Food and Drug Administration (“FDA”), reports CNS Pharmaceuticals (NASDAQ: CNSP), the company now responsible for the drugs’ development. That news was featured in a recent syndicated NetworkNewsAudio (“NNA”) broadcast, which covered CNS Pharmaceuticals’ recent submission of an Investigational New Drug (“IND”)…